The Food and Drug Administration recently gave the thumbs-up for an amended emergency use authorization of the Pfizer-BioNTech vaccine, allowing its use on children aged 12 to 15.
According to health secretary Francisco Duque III: “Pfizer is [for] 12 to 15 years old with or without comorbidity but given insufficient vaccines as of yet, only those with comorbidity are included in the A3 prioritization.”
In a separate message, health undersecretary Rosario Vergeire said: “While we welcome more vaccines that are approved for children and adolescents, due to limited vaccine supply, our vaccination strategy remains the same—prioritize the vulnerable and adhere to our prioritization framework.”
Once vaccine supply is no longer an issue, she said that vaccine experts suggested to “revisit pediatric and adolescent vaccination.”
Meanwhile in China, Sinovac had been granted an EUA for use in children aged 3 to 17.
Vaccine Expert Panel member Dr. Rontgene Solante said that they would study data on the Sinovac jab administered to children within the aforementioned age range the same way they assessed and approved Pfizer for those between 12 to 15 years old.
However, Dr. Edsel Salvana, who belongs to the government’s Technical Advisory Group, said that broadening the scope of age range was “not automatic” and said that Sinovac would still have to apply for it in the Philippines.
Last January, Pfizer was given an EUA for individuals aged 16 or older. In May, the United States Center for Disease Control and Prevention advised that persons 12 and over should get jabbed.
Last Sunday, the Philippines received 1 million doses of Sinovac’s CoronaVac, putting the country’s total vaccine stock at 9.3 million including jabs from AstraZeneca, Pfizer and Sputnik V.